Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISR's Cash to Debt is ranked higher than
91% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. ISR: No Debt )
ISR' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: No Debt

Equity to Asset 0.90
ISR's Equity to Asset is ranked higher than
96% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ISR: 0.90 )
ISR' s 10-Year Equity to Asset Range
Min: -1.09   Max: 0.9
Current: 0.9

-1.09
0.9
F-Score: 4
Z-Score: 19.34
M-Score: -3.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -108.75
ISR's Operating margin (%) is ranked higher than
51% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.78 vs. ISR: -108.75 )
ISR' s 10-Year Operating margin (%) Range
Min: -360.83   Max: -10.59
Current: -108.75

-360.83
-10.59
Net-margin (%) -141.24
ISR's Net-margin (%) is ranked higher than
52% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.09 vs. ISR: -141.24 )
ISR' s 10-Year Net-margin (%) Range
Min: -412.14   Max: -12.01
Current: -141.24

-412.14
-12.01
ROE (%) -43.89
ISR's ROE (%) is ranked higher than
54% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. ISR: -43.89 )
ISR' s 10-Year ROE (%) Range
Min: -659.02   Max: -40.65
Current: -43.89

-659.02
-40.65
ROA (%) -38.04
ISR's ROA (%) is ranked higher than
53% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. ISR: -38.04 )
ISR' s 10-Year ROA (%) Range
Min: -6600   Max: 23500
Current: -38.04

-6600
23500
ROC (Joel Greenblatt) (%) -239.78
ISR's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.33 vs. ISR: -239.78 )
ISR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -876.37   Max: -6.64
Current: -239.78

-876.37
-6.64
Revenue Growth (%) -21.90
ISR's Revenue Growth (%) is ranked higher than
54% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ISR: -21.90 )
ISR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 12.2
Current: -21.9

0
12.2
EBITDA Growth (%) 14.50
ISR's EBITDA Growth (%) is ranked higher than
59% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. ISR: 14.50 )
ISR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 205.5
Current: 14.5

0
205.5
EPS Growth (%) 13.30
ISR's EPS Growth (%) is ranked higher than
58% of the 241 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. ISR: 13.30 )
ISR' s 10-Year EPS Growth (%) Range
Min: -67.8   Max: 233.2
Current: 13.3

-67.8
233.2
» ISR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ISR Guru Trades in

ISR Guru Trades in

Q1 2014

ISR Guru Trades in Q1 2014

Jeff Auxier 14,218 sh (New)
» More
Q2 2014

ISR Guru Trades in Q2 2014

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.20
ISR's P/B is ranked higher than
64% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ISR: 3.20 )
ISR' s 10-Year P/B Range
Min: 0.31   Max: 55
Current: 3.2

0.31
55
P/S 13.00
ISR's P/S is ranked higher than
53% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. ISR: 13.00 )
ISR' s 10-Year P/S Range
Min: 0.56   Max: 285
Current: 13

0.56
285
EV-to-EBIT -16.87
ISR's EV-to-EBIT is ranked higher than
58% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.54 vs. ISR: -16.87 )
ISR' s 10-Year EV-to-EBIT Range
Min: 0.2   Max: 16.8
Current: -16.87

0.2
16.8
Current Ratio 16.65
ISR's Current Ratio is ranked higher than
99% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. ISR: 16.65 )
ISR' s 10-Year Current Ratio Range
Min: 0.07   Max: 16.65
Current: 16.65

0.07
16.65
Quick Ratio 16.34
ISR's Quick Ratio is ranked higher than
99% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. ISR: 16.34 )
ISR' s 10-Year Quick Ratio Range
Min: 0.06   Max: 16.34
Current: 16.34

0.06
16.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.10
ISR's Price/Net Cash is ranked higher than
94% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISR: 5.10 )
ISR' s 10-Year Price/Net Cash Range
Min: 1.92   Max: 33.67
Current: 5.1

1.92
33.67
Price/Net Current Asset Value 4.90
ISR's Price/Net Current Asset Value is ranked higher than
92% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISR: 4.90 )
ISR' s 10-Year Price/Net Current Asset Value Range
Min: 1.47   Max: 35.75
Current: 4.9

1.47
35.75
Price/Tangible Book 3.30
ISR's Price/Tangible Book is ranked higher than
76% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.41 vs. ISR: 3.30 )
ISR' s 10-Year Price/Tangible Book Range
Min: 0.6   Max: 19.44
Current: 3.3

0.6
19.44
Price/Median PS Value 2.50
ISR's Price/Median PS Value is ranked higher than
54% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. ISR: 2.50 )
ISR' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 5.58
Current: 2.5

0.2
5.58
Earnings Yield (Greenblatt) 196.50
ISR's Earnings Yield (Greenblatt) is ranked higher than
98% of the 264 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. ISR: 196.50 )
ISR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.9   Max: 497.6
Current: 196.5

5.9
497.6
Forward Rate of Return (Yacktman) -272.74
ISR's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 266 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.14 vs. ISR: -272.74 )
ISR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: 6.1
Current: -272.74

-9.6
6.1

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
IsoRay, Inc. was organized under Minnesota law in 1983, formerly known as Century Park Pictures Corporation On July 28, 2005, Century changed its name to IsoRay, Inc. The Company provides treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The professional and patient market segments each play a role in the ultimate choice of cancer treatment and the specific isotope chosen for seed brachytherapy treatment. In August 2009, IsoRay Medical obtained treatment for Proxcelan(tm) Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands. Brachytherapy seeds are small devices used in a radiation procedure. IsoRay markets the Proxcelan Cs-131 brachytherapy seed for the treatment of prostate cancer, ocular melanomas, and head and neck cancers, and intends to market Cs-131 for the treatment of other malignant disease, such as lung, in the near future. The Company competes with both public and private medical device, biotechnology and pharmaceutical companies. The disposal of certain radioactive substances and wastes are subject to regulation by several federal and state agencies depending on the nature of the substance or waste material.
» More Articles for ISR

Headlines

Articles On GuruFocus.com
IsoRay Inc. Reports Operating Results (10-K) Sep 28 2010 
IsoRay Inc. Reports Operating Results (10-Q) May 12 2010 
IsoRay Inc. Reports Operating Results (10-Q) Nov 12 2009 
IsoRay Inc. Reports Operating Results (10-Q/A) Sep 02 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Our Partners
Morning Market Losers Sep 30 2014 - BENZINGA

More From Other Websites
IsoRay, Inc. Reports Fiscal Year 2014 Results Sep 30 2014
ISORAY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Sep 30 2014
ISORAY, INC. Files SEC form 10-K, Annual Report Sep 29 2014
Stocks Creating Buzz Today Sep 19 2014
IsoRay Has Tremendous Potential Gaining More Published Peer Reviews Sep 18 2014
IsoRay's Cesium-131 Cancer Treatment Products and Methods to Be Featured in Oral Presentations by... Sep 09 2014
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Sep 04 2014
Medical Device Stocks Report Aug 20 2014
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 14 2014
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 07 2014
IsoRay Announces Positive Peer Review Of Cesium-131 In Treatment Of Metastatic Brain Cancer Aug 05 2014
IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as... Aug 05 2014
Top Biotechnology Stocks Jul 23 2014
Why IsoRay (ISR) Stock Is Spiking Today Jul 14 2014
IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a... Jul 14 2014
IsoRay Announces Its Addition to the Russell Microcap Index Jun 30 2014
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 25 2014
Why IsoRay (ISR) Stock Is Surging Today Jun 24 2014
IsoRay announces Cesitrex cleared by FDA for internal radiation therapy Jun 24 2014
IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer... Jun 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK